secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2026-09-16T13:12:15+00:00
Accession:  0001193125-26-392527
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes appoints Anne C. Whitaker to board, expanding to 11 directors
----------------------------------------------------------------------

- Board increased from 10 to 11 directors; Whitaker effective Sept. 14, 2026, term through 2027 AGM.
- Whitaker receives $600,000 initial equity award (50% options, 50% RSUs), vesting in 3 annual installments.
- She will receive standard annual cash retainer and equity grant per proxy statement director compensation.
- CEO Blair Jackson cites Whitaker's commercial and operational expertise in neuroscience-focused pipeline.
- Chairman Richard Pops welcomes Whitaker, citing her CEO and board experience across pharma/biotech.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000119312526392527/0001193125-26-392527-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000119312526392527/alks-20260914.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-392527

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer